SCS
NBIX icon

Sound Capital Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Sound Capital Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Buy
+3,447
New +$511K 0.14% 117

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Sound Capital Solutions's NBIX Position: Q2 2026 in Review

Sound Capital Solutions opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 3,447 shares worth $581K. The stake represents 0.14% of the portfolio and ranks #117 among its holdings.

733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sound Capital Solutions held 3,447 shares of Neurocrine Biosciences worth $581K as of Q2 2026.
  • Neurocrine Biosciences was a new Sound Capital Solutions position in Q2 2026.
  • Neurocrine Biosciences made up 0.14% of Sound Capital Solutions's portfolio in Q2 2026, its #117 holding.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sound Capital Solutions's 13F filing for Q2 2026, filed 13 Aug 2026.